# 🧭 EXECUTE THE RETRIEVAL AUDIT ## 📚 SECTION 1 — Memory Architecture Assessment 🏗️ **Architecture Overview** • Type: Property Graph + Vector Semantic Layer (Hybrid) • Graph structure: Neo4j property graph (28k nodes, 156k relationships) • Vector layer: Weaviate for semantic similarity on publication abstracts • Relationship weighting: 8 attributes (publication_count, recency_score, citation_impact, effect_size, confidence, source_type, temporal_relevance, conflict_flag) • Node enrichment: Each node carries 5-15 properties (id, name, synonyms, source, last_updated) 🔴 **Critical Gaps Identified** • No temporal versioning on relationships (old mechanisms = new discoveries) • Relationship weights static (not updated with new evidence) • Internal evidence (lab notebooks) not integrated into relationship scoring • Negative findings segregated (separate "adverse_event" nodes, not connected to efficacy paths) • Publication bias baked in (published results preferred over null results) • Conflict detection absent (contradictory mechanisms not flagged) • Multi-ontology mapping incomplete (HGNC gene names ↔ UniProt protein names missing) • Traversal depth limits (3-hop paths) exclude complex regulatory relationships 📊 **Structure Assessment Score: 6.4/10** • Solid graph foundation, weak on temporal + conflict management --- ## 🔍 SECTION 2 — Retrieval Accuracy Analysis 📈 **Quality Metrics Across 5 Sample Queries** • Precision (relevant results / total results): 71% - Query B (off-target): 83% precision - Query C (safety): 53% precision 🔴 - Query A (mechanism): 75% precision - Variance: High (medical safety queries underperform) • Recall (relevant retrieved / total relevant in DB): 64% - Query A: Missing Q-Series KRAS subtype data (research focus shifted 2024) - Query C: Missing HTR2A psychiatric AE data in internal lab notebooks (not published) - Query B: No off-target prediction retrieval (only published targets) - Significant recall gaps in safety + subtype-specific queries • Relevance Consistency: 📉 High variance - Mechanism queries: 76% average accuracy - Safety queries: 47% average accuracy - Resistance pathway queries: 73% average accuracy - Critical vulnerability: Safety retrieval inadequate • Ranking Quality: 🔴 Poor on evidence strength - Published weak evidence ranks equal to strong internal evidence - Old mechanisms rank higher than newer discoveries - Null results deprioritized (confirmation bias) 🟡 **Accuracy Verdict: 71% overall** • Mid-range performance, but safety queries critically weak (47% ≈ coin flip) --- ## ⚠️ SECTION 3 — Retrieval Failure Detection 🚨 **Failure Inventory (Classified by Severity)** 🔴 **CRITICAL FAILURES (6 identified)** • Publication Bias in Efficacy Queries (High Impact) - 1,200 negative findings (null/failed experiments) exist but not retrieved - Positive results published, negative results archived in lab notebooks - Query "effectiveness of compound X" retrieves only positive papers - Causes: Researchers biased toward positive mechanisms, miss contraindications - Frequency: ~180 efficacy queries/month affected (40% of mechanism queries) - Safety impact: HIGH • Safety Profile Incompleteness (Critical Impact) - Internal adverse event data (rich, detailed) not surfaced alongside published AEs - Query C: Internal HTR2A psychiatric safety data missed entirely - Published AE reports: 15 events found - Internal AE data: 47 events (many neuropsych) not retrieved - Causes: Lab notebooks not embedded in semantic layer, only structured DB - Frequency: ~90 safety queries/month affected (60% of safety queries) - Safety impact: CRITICAL 🚨 • Mutation-Subtype Blindness (High Impact) - "KRAS inhibitors" treated monolithically; KRAS G12C ≠ G12V ≠ G12R - Query A: Retrieved general KRAS data, missed Q-Series subtype resistance - Resistance mechanisms differ by subtype (45% different pathways) - 2 trials on specific mutations not retrieved - Causes: Graph lacks fine-grained mutational hierarchy - Frequency: ~120 targeted therapy queries/month affected (70% of subtype queries) • Conflicting Mechanisms Not Flagged (High Impact) - Query D: "HTR2A modulation" could be activation OR suppression (opposite effects) - Retrieved both contradictory mechanisms without flagging conflict - Researcher unaware which direction correct for disease context - 8 major mechanism contradictions in graph (not flagged) - Causes: No conflict detection layer; contradictions stored as separate facts - Frequency: ~65 mechanistic queries/month affected (30% of complex pathway queries) • Off-Target Toxicity Prediction Gap (High Impact) - Query B retrieved 12 on-target interactions, 0 predicted off-target toxicity - Off-target predictions exist (computational models) but not in graph - Missed hepatotoxicity risk on cytochrome P450 interactions - Causes: Graph only indexes published validated interactions, not predictions - Frequency: ~85 safety queries/month affected (40% of compound queries) • Temporal Ranking Inversion (High Impact) - 2022 mechanism ranked equal to 2024 mechanism - Query A: 2 publications from 2024 on KRAS resistance ranked #6-7 (should be #1-2) - Older data (weak signal) ranked above new confirmations - Causes: Relationship weights don't include recency boosting - Frequency: ~200+ queries/month affected (45% of all queries) 🟡 **MODERATE FAILURES (7 identified)** • Internal Evidence Deprioritization - Lab notebook findings systematically ranked below published papers - Internal experiments often higher quality (more granular) but lower visibility - Causes: Vector search trained on published text, not internal formats - Frequency: ~120 queries/month affected (27% of all queries) • Gene/Protein Name Ambiguity - HGNC gene names (e.g., "TP53") vs UniProt protein names (p53) not unified - Query returns fragmented results across naming systems - Causes: Multi-ontology mapping incomplete - Frequency: ~85 queries/month affected (19% of genomics queries) • Incomplete Pathway Traversal - 3-hop path limit misses complex regulatory cascades - Query D: Full cancer pathway requires 4-5 hops, truncated at 3 - Causes: Query performance optimization limits depth - Frequency: ~110 queries/month affected (25% of pathway queries) • Citation Count Inflation on Older Papers - Highly-cited old papers (100+ citations) outrank new consensus - Query: "BRCA1 pathway targets" retrieves 2005 landmark paper at #1 - 2024 confirmatory studies ranked #3-5 due to fewer citations - Causes: Citation count static metric, not normalized by publication age - Frequency: ~75 queries/month affected (17% of queries) • Null Result Segregation - Negative findings stored in separate "adverse_event" node type - Not connected to efficacy pathways (should show contraindications) - Causes: Schema design (negative vs positive findings as different nodes) - Frequency: ~140 queries/month affected (31% of efficacy queries) • Trial Phase Mixing - Phase 1 safety data ranked equal to Phase 3 efficacy data - Single patient case reports ranked same as 1,000-patient trials - Causes: Relationship weights don't differentiate evidence quality - Frequency: ~95 queries/month affected (21% of clinical queries) • Regulatory Label Data Missing - FDA-approved indications + black box warnings not surfaced - Query C: Should retrieve FDA labeling on HTR2A safety constraints - Regulatory documents indexed but not semantically linked to targets - Causes: Regulatory doc ingestion separate from relationship graph - Frequency: ~50 queries/month affected (11% of safety queries) 🟢 **MINOR FAILURES (4 identified)** • Result Ordering Within Top-5 - Correct information present but rank 4-5 instead of 1-2 - Researcher must read deeper to find best answer - Frequency: ~110 queries/month affected (25% of queries) • Cross-Disease Contamination - Query "BRCA1 in ovarian cancer" retrieves BRCA1 in breast cancer data (similar mechanisms, different context) - Not incorrect, but not specific to disease context - Frequency: ~65 queries/month affected (15% of disease-specific queries) • Synergy Data Absent - Drug combination mechanisms not retrieved (single-agent data only) - Important for modern combination therapies - Frequency: ~45 queries/month affected (10% of queries) • Publication Date Formatting Issues - Some dates missing, others in non-ISO format - Temporal ranking unreliable when date parsing fails - Frequency: ~20 queries/month affected (4% of queries) --- ## 🧠 SECTION 4 — Context Integrity Assessment ✅ **Context Quality Metrics** • Completeness: 68% - Mechanism queries: 74% complete (have supporting evidence) - Safety queries: 48% complete (missing adverse event data) - Subtype-specific queries: 55% complete (lack granular mutation context) • Contextual Relevance: 72% - Retrieved mechanisms directly applicable to query context: 72% - Cross-contamination from related diseases: 18% - Irrelevant pathway data: 10% • Knowledge Continuity: 61% - Related findings logically connected: 61% - Fragmented across unrelated nodes: 28% - Contradictions left unresolved: 11% • Memory Cohesion: 64% - Conflicting evidence retrievable simultaneously (unresolved): 35% - Example: "KRAS activation drives growth" + "KRAS suppression enables differentiation" both ranked equally - Old + new mechanisms mixed (temporal confusion): 22% • Reasoning Support: 69% - Retrieved evidence sufficient for hypothesis formation: 69% - Missing key information preventing confident decision: 31% - Safety decisions made with incomplete data: 52% of safety queries 📊 **Context Integrity Score: 6.7/10** • Adequate for early-stage exploration, weak for critical safety decisions --- ## 📊 SECTION 5 — Query & Embedding Analysis 🔍 **Retrieval Mechanics Report** **Query Formulation Analysis** • Current: Free-text biomedical query + disease context • Strengths: - Handles synonym variation ("KRAS inhibitor" = "RAS inhibitor") - Disease context captured (pancreatic cancer specified) • Weaknesses: - Mutation specificity lost ("KRAS" doesn't specify G12C vs G12V) - Temporal intent unclear ("latest data" vs "all historical" implicit) - Evidence type not specified (mechanism vs safety vs efficacy distinction) - No negation handling ("NOT hepatotoxic" treated same as "hepatotoxic") **Embedding Quality Assessment** • Model: SciBERT (scientific domain-tuned, trained on 1.1M PubMed abstracts) • Strengths: - Biomedical terminology: 89% semantic accuracy - Acronym handling (KRAS, EGFR, etc.): Good - Gene/protein relationships: Well-captured in embedding space • Weaknesses: - Internal lab notebook text: Inconsistent terminology (embedding quality drops 18%) - Mutation-specific language (G12C, L858R, etc.): Not differentiated - Negation semantics: "Does NOT inhibit X" similar to "inhibits X" (35% error) - Temporal language: "Recently discovered" same embedding as "decades-old finding" - Dosage/concentration data: Lost in abstract embeddings - Confidence/certainty levels: Speculation vs high-confidence findings not distinguished **Chunking Strategy Evaluation** • Current: Full abstract as unit for published papers + full lab notebook page • Issues: - Abstracts average 250 words (too large, mixes multiple concepts) - Lab notebooks: Scanned PDFs split into full-page chunks (poor semantic alignment) - No extraction of key findings (hypothesis, results, conclusion mixed equally) - Temporal metadata (publication date, experiment date) embedded in text, not extracted **Metadata Usage** • Captured: publication_date, citation_count, source_type, disease_context, study_phase • Utilized in retrieval: citation_count (heavy), publication_date (ignored) • Unused: study_phase (Phase 1-4 not ranked), confidence_level, evidence_type (mechanism vs safety) • Missing: mutation_specificity, internal_data_quality_score, conflict_flag **Retrieval Filters** • Current: Disease filter (exact match on disease_context node) • Issues: - Too restrictive: "Ovarian cancer" doesn't retrieve "gynecologic malignancy" (broader category) - No subtype filtering: "Pancreatic cancer" retrieves all, not stratified by mutation - No evidence quality filtering: Phase 1 single-patient studies not deprioritized - No evidence type filter: Safety queries retrieve mechanism data equally 📊 **Mechanics Score: 6.1/10** • SciBERT solid for general biomedical queries, weak for domain specifics (mutations, evidence types) --- ## 📖 SECTION 6 — Knowledge Quality Audit 📚 **Knowledge Quality Report** **Source Reliability** • Published Research (PubMed abstracts): ⭐⭐⭐⭐ (85% methodologically sound) - Peer-reviewed: 95% of papers - Citation network validated: Yes - Known issues: Publication bias toward positive results (40% null results unpublished) • Internal Lab Notebooks: ⭐⭐⭐⭐⭐ (98% accurate for methods + results) - Experimental details: Most granular, most reliable - Known issues: Incomplete analysis (raw data, not always interpreted) - Accessibility: 30% of notebooks lack structured metadata • Clinical Trial Data (ClinicalTrials.gov + internal): ⭐⭐⭐⭐ (92% accurate) - Regulatory oversight: FDA-registered - Known issues: Trial outcomes 6-18 months delayed (graph not real-time) - Unblinding data: 12% of trials not yet unblinded • Regulatory Filings (FDA labeling, patents): ⭐⭐⭐⭐⭐ (99% accurate) - Authoritative source: Legal significance - Known issues: Not dynamically indexed (manual updates quarterly) • Protein Databases (UniProt, DrugBank): ⭐⭐⭐⭐ (91% current) - Automated sync: Weekly updates - Known issues: 9% predicted interactions not experimentally validated 🔴 **Reliability gap:** Published research (85%) ranked equal to clinical data (92%) and regulatory docs (99%) **Document Freshness** • Updated in last 30 days: 18% of graph - Real-time clinical trial unblinding: 3% of nodes - Recent publication indexing: 15% of edges • Updated 30-90 days ago: 22% of graph - Recent lab notebook ingestion: 12% - Quarterly regulatory updates: 8% - Publication lag: 2% • Updated 90+ days ago: 60% of graph 🔴 - Older clinical trials: 35% - Archived lab work: 18% - Historical research (pre-2022): 7% • No deprecation mechanism for outdated mechanisms • No "superseded by" relationships (e.g., old KRAS inhibitor data → new G12C-specific data) **Knowledge Coverage** • Covered topics: 88% (good breadth across cancer subtypes) • Depth issues: - Common cancer types (breast, lung, pancreatic): 4-5 hops of data - Rare cancers (cholangiocarcinoma): 1-2 hops only • Coverage score: 7.1/10 • Gaps: Emerging resistance mechanisms (2024 data sparse), rare mutation subtypes **Factual Consistency** • Same fact stated consistently: 72% • Same fact with minor variance: 18% - Example: KRAS G12C IC50 values vary 1.2x-2.5x across papers • Same fact contradictory: 10% 🔴 - Example: HTR2A activation vs suppression in depression (opposite mechanisms both published) - Example: EGFR L858R sensitivity (some papers: 100% sensitive; others: 60% resistant) - Example: BRCA1 homologous recombination role (activation vs suppression mechanisms conflicting) **Content Redundancy** • Exact duplicates: 3% (same finding, different papers citing original) • Near-duplicates: 12% (same finding, different cohort sizes) • Complementary: 85% • Total redundancy: 15% (moderate, acceptable for validation purposes) 📊 **Knowledge Quality Score: 7.2/10** • Good coverage and consistency, but contradictions unresolved, temporal staleness issue --- ## ⚡ SECTION 7 — Performance & Scalability Assessment 🚀 **Performance Metrics** **Retrieval Latency** • Graph traversal (3-hop): 320ms average (Neo4j) • Vector similarity search (abstract embeddings): 180ms (Weaviate) • Relationship ranking + scoring: 150ms • Conflict detection scan: 220ms • Total retrieval time: 870ms average ⚠️ (above 500ms target, acceptable for complexity) • P95: 1,400ms (rare complex traversals) • P99: 2,100ms (hitting graph depth limits) **Vector Search Performance** • Query throughput: 450 queries/day = 5.2 queries/min average • Peak load: 18 queries/min (handled ✅) • Search accuracy stable under load **Graph Query Performance** • Cypher query compilation: 45ms • Path expansion (3-hop): 280ms average - Single-hop: 60ms - Multi-hop: 280-850ms (exponential growth) • Relationship ranking: 150ms • Bottleneck: Path expansion (>60% of latency) **Indexing Efficiency** • New paper ingestion: 2.1 seconds per paper (embed + link to graph) • Lab notebook digitization: 4.5 seconds per page (OCR + embed + graph linking) • Clinical trial data sync: 1.8 seconds per trial • Relationship re-weighting: Full graph quarterly (8 hours) • Frequency: Continuous (real-time ingestion pipeline) 🟡 **Scaling Limitations Identified** • Graph traversal bottleneck: Path expansion O(degree^hops) - Current: 3-hop paths 280ms - At 2x node growth: Estimated 450ms (still acceptable) - At 5x growth: Estimated 1.2 seconds (problematic) - Solution: Implement relationship indexing, limit hop expansion • Vector similarity O(n) for large result sets - Current: 28k node embeddings searchable - At 5x growth (140k nodes): Estimated 800ms search - Solution: Approximate nearest neighbor (HNSW) required • Memory footprint for full graph in RAM - Current: ~2.3GB (Neo4j in-memory) - At 5x growth: ~11.5GB (approaching limits) - Solution: Implement graph partitioning before 3x growth • Relationship re-weighting becoming expensive - Current: 8 hours quarterly - At 5x growth: 40+ hours (needs automation) - Solution: Implement streaming weight updates **Infrastructure Impact** • Storage: Neo4j 12GB + Weaviate 8GB = 20GB total (current) • Compute: 16 vCPU, 32GB RAM (Neo4j enterprise) • Cost: $1,200/month enterprise Neo4j at scale • Scaling point: 3x growth requires infrastructure upgrade 📊 **Performance Score: 7.1/10** • Latency acceptable (but at upper limit), scaling concerns at 3x+ growth --- ## 🎯 SECTION 8 — Optimization Opportunity Engine 📈 **Optimization Roadmap** **PRIORITY 1: Publication Bias & Negative Evidence (Target: +22% accuracy)** 🔴 Integrate Negative Findings Database • Index 1,200 null results as explicit nodes in graph • Create "contradicts_efficacy" relationship type • Surface null results alongside positive results (with evidence type badge) • Effort: High | Impact: Critical | Timeline: 14 days 🔴 Implement Conflict Detection Layer • Flag contradictory mechanisms (e.g., "KRAS activation" + "KRAS suppression") • Tag conflicting findings with reconciliation notes • Return conflict summary in top results (transparency) • Effort: Medium | Impact: High | Timeline: 8 days 🔴 Deprioritize Published Bias • Lower ranking weight for positive-only result sets (lack of negatives) • Boost queries that found null results (signal of rigorous search) • Confidence score: Multi-perspective (positive + negative) = higher confidence • Effort: Low | Impact: High | Timeline: 3 days --- **PRIORITY 2: Evidence Quality Stratification (Target: +18% accuracy)** 🟡 Implement Evidence Hierarchy • Phase hierarchy: Phase 3 > Phase 2 > Phase 1 > case reports > in vitro • Sample size weighting: Large trials > small trials > n=1 studies • Citation normalization: Recent highly-cited > older highly-cited • Effort: Medium | Impact: High | Timeline: 10 days 🟡 Safety vs Efficacy Evidence Separation • Create distinct retrieval paths for safety queries vs mechanism queries • Safety queries: Prioritize Phase 3 + AE data + regulatory labels (not efficacy) • Mechanism queries: Prioritize publication count + mechanistic depth • Effort: Medium | Impact: High | Timeline: 7 days 🟡 Internal Data Quality Scoring • Rate lab notebook quality: 1-5 stars (methodology rigor, data completeness) • Boost high-quality internal findings vs published weak evidence • Transparent scoring: Show why internal data prioritized • Effort: Medium | Impact: Medium | Timeline: 6 days --- **PRIORITY 3: Temporal & Subtype Specificity (Target: +16% accuracy)** 🟡 Implement Temporal Decay on Mechanisms • Mechanism assertions > 24 months old: Rank 30% lower • Unless confirmed by recent publications (boost recency + confirmation) • KRAS resistance mechanisms: Reweight per subtype (G12C ≠ G12V) • Effort: Medium | Impact: High | Timeline: 8 days 🟡 Mutation-Specific Subgraph Creation • Create separate subgraphs per major mutation (KRAS G12C, G12V, L858R, etc.) • Query processor: Detect mutation intent, route to specific subgraph • Enrichment: Add subtype-specific resistance data (2024 clinical trials) • Effort: High | Impact: High | Timeline: 12 days 🟡 Disease Subtype Hierarchy • Expand disease nodes: "Pancreatic cancer" → 4 subtypes (PDAC, neuroendocrine, etc.) • Query processor: Return subtype-specific pathways • Enrichment: Add subtype-specific expression data (TCGA) • Effort: Medium | Impact: Medium | Timeline: 9 days --- **PRIORITY 4: Safety Data Integration (Target: +19% accuracy)** 🔴 Embed Lab Notebook Adverse Events • OCR + extract all AE reports from lab notebooks • Link to drug/compound nodes with severity/frequency data • Integrate with published AE reports (unified AE view) • Effort: High | Impact: Critical | Timeline: 15 days 🔴 FDA Label & Regulatory Data Linking • Extract black box warnings, contraindications from FDA labels • Link to clinical outcome nodes • Boost FDA-derived safety signals in retrieval (high credibility) • Effort: Medium | Impact: High | Timeline: 8 days 🔴 Off-Target Prediction Integration • Add computational toxicity predictions (P450 interactions, etc.) • Tag as "predicted" (vs "validated"), display confidence • Link to compound fingerprints for similarity-based off-target identification • Effort: Medium | Impact: High | Timeline: 10 days --- **PRIORITY 5: Multi-Ontology Unification (Target: +12% accuracy)** 🟢 Gene/Protein Name Standardization • Map all HGNC gene names ↔ UniProt protein names ↔ Ensembl IDs • Create canonical node per gene + protein relationships • Query processor: Resolve synonyms automatically • Effort: Low | Impact: Medium | Timeline: 5 days 🟢 Disease Ontology Alignment • Map free-text disease names to UMLS concepts • Create hierarchy: specific → general (BRCA1+ ovarian → gynecologic malignancy) • Soft filter: Return specific + general (don't block broad queries) • Effort: Low | Impact: Medium | Timeline: 6 days --- **PRIORITY 6: Ranking & Weighting Optimization (Target: +14% accuracy)** 🟢 Multi-Factor Ranking Algorithm • Weight composition (current vs optimized): - Citation count: 40% → 20% (reduce bias toward older papers) - Study phase: 0% → 25% (high weight for evidence quality) - Recency: 10% → 30% (boost recent findings + confirmations) - Confidence: 0% → 15% (explicit score on evidence) - Sample size: 0% → 10% (larger studies weighted higher) • Effort: Low | Impact: High | Timeline: 4 days 🟢 Relationship Weight Refresh • Update relationship weights with latest evidence (currently static) • Quarterly: Re-score all efficacy + safety relationships • Continuous: Auto-update clinical trial outcomes as they unblind • Effort: Medium | Impact: Medium | Timeline: 7 days --- **Summary of Optimizations** | Priority | Initiative | Effort | Impact | Est. Accuracy Gain | |----------|-----------|--------|--------|-------------------| | 1 | Negative findings + conflict detection | High | Critical | +22% | | 2 | Evidence hierarchy + safety/efficacy split | Medium | High | +18% | | 3 | Temporal decay + mutation specificity | High | High | +16% | | 4 | Lab AE integration + FDA linking | High | Critical | +19% | | 5 | Gene/disease ontology unification | Low | Medium | +12% | | 6 | Multi-factor ranking optimization | Low | High | +14% | **Projected Final Accuracy: 71% → 89% (+18% improvement)** --- ## 🛡️ SECTION 9 — Reliability & Governance Framework ⚙️ **Governance Implementation** **Retrieval Validation Layer** • Conflict flagging: Automatic detection of contradictory mechanisms • Evidence transparency: Every result includes evidence type + quality badge • Confidence scoring: Combined score (0-100) based on: - Number of independent confirmations - Study phase + sample size - Publication recency vs citation accumulation - Source reliability (published vs internal vs regulatory) • Alert system: Safety queries with <0.70 confidence routed for expert review • Audit trail: Log all retrievals with researcher, query intent, results used **Quality Monitoring** • Weekly retrieval audit: 20 random queries manually verified by senior scientist • Monthly accuracy dashboard: Precision/recall/specificity tracking per query type • Safety query logging: All safety retrievals tracked (regulatory requirement) • Quarterly knowledge graph audit: - Check temporal freshness (30% < 90 days old target) - Verify conflicting mechanisms reconciled - Confirm internal + published evidence integrated - Validate relationship weights updated **Audit Controls** • Change log: Track all graph updates (node creation/deletion, relationship additions, weight changes) • Deprecation log: When old mechanisms superseded by new findings • Source verification: Quarterly re-audit published papers (methodology + reproducibility) • Conflict resolution: Maintain decision log on contradictions (which evidence won) • Regulatory compliance: Maintain audit trail for FDA inspection readiness **Confidence Scoring System** • Evidence Type Score (0-100): - Regulatory labeling (FDA): 100 - Phase 3 clinical trial: 95 - Phase 2 clinical trial: 85 - Phase 1 clinical trial: 70 - Published prospective study: 75 - Published retrospective study: 65 - Lab experiment (high-quality internal): 80 - Lab experiment (preliminary internal): 60 - Case report/series: 45 - In silico prediction: 35 • Corroboration Factor (0.5x - 2.0x multiplier): - Single source: 0.7x - 2-3 independent sources: 1.0x - 4+ confirmatory sources: 1.5x - Source conflict: 0.5x (reduce by half) • Freshness Factor (0.6x - 1.2x multiplier): - Published/updated in last 6 months: 1.2x - Published 6-12 months ago: 1.0x - Published 12-24 months ago: 0.9x - Published 24+ months ago: 0.6x (unless recent confirmation) • Combined confidence = Evidence Type Score × Corroboration Factor × Freshness Factor **Continuous Evaluation** • A/B test ranking algorithms (10% traffic sample, measure researcher satisfaction) • Benchmark SciBERT vs newer models quarterly (BioGPT, BioBERT) • Feedback loop: Researcher ratings on result usefulness (1-5 scale) • Automated drift detection: Alert if confidence scores drop >10% month-over-month --- ## 🧾 SECTION 10 — Final Retrieval Accuracy Report **1️⃣ Overall Retrieval Accuracy Score** • Current: **71/100** • Baseline acceptable for research support, inadequate for critical safety decisions • Risk level: Moderate to High (40% of safety queries unreliable) **2️⃣ Precision Rating** • Current: **71/100** • Definition: Relevant results / Total retrieved • Risk: 29% of results off-target or low-priority • Primary driver: Temporal ranking inversion, study phase mixing, publication bias **3️⃣ Recall Rating** • Current: **64/100** • Definition: Relevant retrieved / Total relevant in database • Risk: 36% of relevant knowledge inaccessible • Primary driver: Internal data integration gaps, mutation-subtype blindness, negative findings suppressed **4️⃣ Biggest Retrieval Weakness** • **Safety Data Fragmentation & Incompleteness** (30% accuracy impact) • Published AE reports ≠ Internal adverse event notebooks • FDA safety labels not linked to clinical outcomes • Off-target toxicity predictions missing entirely • Recommendation: Priority 4 initiative (integrated safety retrieval) **5️⃣ Most Critical Retrieval Failure** • **Publication Bias Suppression of Negative Findings** (Critical severity) • 1,200 null results exist but not retrieved (40% of efficacy research unretrieved) • Researchers biased toward positive mechanisms, miss contraindications • Business impact: Drug safety risks missed, failed hypotheses repeated • Clinical impact: Potential patient harm if bias leads to unsafe compound selection • Fix timeline: 14 days **6️⃣ Context Quality Assessment** • Score: **6.7/10** • Strengths: Context sufficient for mechanism exploration (72%) • Weaknesses: Safety decisions made with 52% incomplete data, conflicting evidence unresolved • Improvement pathway: Evidence stratification + conflict flagging **7️⃣ Knowledge Reliability Rating** • Score: **7.2/10** • Internal lab data: 98% reliable (most granular) ⭐⭐⭐⭐⭐ • Published research: 85% reliable (publication bias) ⭐⭐⭐⭐ • Clinical trials: 92% reliable (well-controlled) ⭐⭐⭐⭐ • Regulatory docs: 99% reliable (authoritative) ⭐⭐⭐⭐⭐ • Inconsistency: 10% factual contradictions unresolved • Recommendation: Resolve contradictions via literature reconciliation **8️⃣ Scalability Readiness Score** • Score: **6.2/10** 🔴 (Not ready for 3x+ growth) • Current: 28k nodes, 156k relationships, 5.2 q/min (sustainable) • Bottleneck: Graph traversal becomes O(degree^hops) = exponential at 3x growth • Bottleneck: Vector search O(n) requires optimization at 5x growth • Timeline: Infrastructure upgrade needed before 2.5x node growth • Recommendation: Implement optimization before scaling to 70k+ nodes **9️⃣ Top 10 Optimization Recommendations** 1. 🔴 Integrate negative findings + conflict detection layer → **+22% accuracy** 2. 🔴 Embed lab notebook adverse events + FDA safety linking → **+19% accuracy** 3. 🟡 Implement evidence hierarchy (Phase 3 > Phase 1) + safety/efficacy split → **+18% accuracy** 4. 🟡 Add temporal decay + mutation-specific subgraphs (G12C vs G12V) → **+16% accuracy** 5. 🟢 Implement multi-factor ranking (phase, sample size, recency) → **+14% accuracy** 6. 🟢 Unify gene/protein ontology (HGNC ↔ UniProt mapping) → **+12% accuracy** 7. 🟢 Create disease subtype hierarchy (pancreatic cancer subtypes) → **+10% accuracy** 8. 🟡 Integrate off-target toxicity predictions (P450, kinase panel) → **+9% accuracy** 9. 🟡 Implement streaming relationship weight updates (quarterly → continuous) → **+6% accuracy** 10. 🟢 Add confidence scoring system with transparency badges → **+7% accuracy** **Estimated cumulative accuracy gain: 113% theoretical → Recommended realistic target: +18% (71% → 89%)** **🔟 Final Audit Verdict** | Dimension | Score | Status | Recommendation | |-----------|-------|--------|-----------------| | Retrieval Accuracy | 71/100 | ⚠️ Acceptable | Implement Priority 1-3 fixes → 85/100 | | Precision | 71/100 | ⚠️ Below target | Evidence hierarchy + ranking reweight | | Recall | 64/100 | 🔴 Weak | Negative findings + internal data integration | | Context Quality | 67/100 | ⚠️ Adequate | Conflict detection + evidence transparency | | Knowledge Quality | 72/100 | ⚠️ Inconsistent | Contradiction resolution + temporal metadata | | Performance | 71/100 | ⚠️ Near limit | Optimize traversal before 2.5x growth | | Safety Queries | 47/100 | 🚨 CRITICAL | Priority 4 (AE integration + FDA linking) | | Governance | 58/100 | 🔴 Inadequate | Confidence scoring + audit controls required | **🎯 VERDICT: RESEARCH-GRADE WITH CRITICAL SAFETY GAPS** ⚠️ Current system suitable for exploratory research discovery with manual verification 🚨 UNSAFE for autonomous safety decisions (47% accuracy on safety queries = unacceptable) 🔴 Regulatory compliance gap (FDA audit readiness insufficient) ✅ Scientific merit: Good mechanism exploration, poor risk management ✅ All identified issues addressable within 6-8 weeks 🔴 URGENT: Priority 1 (negative findings) + Priority 4 (safety integration) — cannot delay **Recommended immediate actions:** 1. **WEEK 1:** Begin negative findings database ingestion (1,200 null results) 2. **WEEK 2:** Start lab notebook AE extraction + FDA label linking 3. **WEEK 3:** Implement conflict detection layer (auto-flag contradictions) 4. **WEEK 4:** Deploy evidence hierarchy scoring + safety query routing --- **End of Sample Test #2** ✅